Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage biotechs in the bunch. The analysts’ selections for the upcoming year span ...

SAN JOSE — Zebra Technologies and bioMerieux reported to the state Employment Development Department their separate decisions to cut jobs in moves that will eliminate a combined 196 positions in San ...

HIGHLAND PARK Fla. — A Florida nonprofit is on a mission to revive the state’s farmland with sustainability in mind. Biotech Applied Research is turning waste into “biochar,” a charcoal-like material.

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the science—blockbuster obesity drugs, advances in cancer treatments, novel cell ...

Microbial ecology in the Middle East and North Africa (MENA) region represents a rapidly evolving frontier at the ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...